Nigeria Liver Diseases Therapeutics Market Report 2022 to 2030

Nigeria Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Nigeria liver disease therapeutics market will reach a value of $35 Mn from $21 Mn in 2022, growing at a CAGR of 6.7 % during 2022-2030. Liver disease therapeutics in Nigeria is dominated by a few domestic pharmaceutical companies such as May & Baker Nigeria, GSK Nigeria, and Swiss Pharma Nigeria. The market in Nigeria is segmented into different types of diseases and different therapy types. Some of the major factors affecting the market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10NGPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Nigeria AUTHOR: Dr. Vishwa Modhia

Buy Now

Nigeria Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Nigeria Liver Disease Therapeutics market will reach a value of $35 Mn from $21 Mn in 2022, growing at a CAGR of 6.7 % during 2022-2030.

Nigeria is a lower middle-income, developing country located in West Africa with a coast on the Gulf of Guinea and the Atlantic Ocean. The majority of Nigeria's illness burden is caused by preventable diseases, with poverty playing a significant role. Because of a lack of demographic data and a scarcity of scientifically competent research, it is impossible to properly define the burden of viral hepatitis in Nigeria.

The Nigerian drug regulatory body has currently authorized only lamivudine and interferon-alfa-2a for the treatment of viral hepatitis. According to the latest WHO data published in 2020 Liver Disease Deaths in Nigeria reached 38,326 or 2.59% of total deaths. The age-adjusted death rate is 41.99 per 100,000 of the population ranks Nigeria 21^st in the world. Nigeria's government spent 3.4 % of its GDP on healthcare in 2020.

nigeria liver disease therapeutics market analysis

Market Dynamics

Market Growth Drivers

The Nigerian Association for the Study of the Liver has created a draught document outlining guidelines for the treatment of viral hepatitis. The development of these recommendations is a significant move toward promoting modern hepatology practice in Nigeria. Organizations like the Tropical Health and Education Trust (THET) are working to raise standards in a variety of fields in Nigeria and across Africa. These aspects could boost the liver disease therapeutics market in Nigeria.

Market Restraints

Because of the high frequency of hepatitis B and hepatitis C, which frequently coincide with HIV infection, liver damage is widespread. Antiviral treatments are costly, and medications are frequently unavailable, even when they can be obtained. Nigeria is Africa's most populous country, yet despite enormous oil deposits, little of the country's newly discovered wealth has made its way into the healthcare sector. However, the cost of treating these ailments is out of reach for the average Nigerian. Even though there is a national response to viral hepatitis, less than 5% of patients infected with viral hepatitis B have ever sought clinical services. This is especially critical for rural dwellers, who account for a sizable proportion of HBV patients in Nigeria. Despite the Made in Nigeria (MINE) project's target of raising it to 20%, manufacturing activity represents barely 10% of Nigeria's GDP.

Competitive Landscape

Key Players

May & Baker Nigeria Plc: May & Baker is a Nigerian pharmaceutical company that produces a range of therapeutics, including those for liver disease. Its liver disease products include Silymarin and Ursodeoxycholic acid
GSK Nigeria: GSK Nigeria is a subsidiary of the global pharmaceutical company GlaxoSmithKline, and produces a variety of therapeutic products, including those for liver disease
Swiss Pharma Nigeria Limited: Swiss Pharma Nigeria is a Nigerian pharmaceutical company that produces a range of therapeutic products, including those for liver disease

Healthcare Policies and Reimbursement Scenarios

In Nigeria, the regulation of liver disease therapeutics is overseen by the National Agency for Food and Drug Administration and Control (NAFDAC), which is responsible for ensuring that all pharmaceutical products, including liver disease therapeutics, meet safety, efficacy, and quality standards. To be approved for use in Nigeria, liver disease therapeutics must be registered with NAFDAC, and manufacturers must comply with Good Manufacturing Practices (GMP) and other regulatory requirements.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Nigeria Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.